Top Page
Fuso Pharmaceutical Industries,Ltd.
(4538)
Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)
Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model
Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 60.56B | 55.41B | 51.02B | 49.63B | 49.25B |
| Gross Profit | 16.53B | 13.52B | 13.74B | 13.40B | 14.11B |
| EBITDA | 6.29B | 4.20B | 4.63B | 4.47B | 4.79B |
| Net Income | 2.78B | 1.38B | 1.60B | 1.48B | 1.61B |
Balance Sheet | |||||
| Total Assets | 79.05B | 75.80B | 72.47B | 69.33B | 69.88B |
| Cash, Cash Equivalents and Short-Term Investments | 6.26B | 5.12B | 8.01B | 7.35B | 7.07B |
| Total Debt | 21.29B | 12.72B | 12.63B | 12.09B | 13.20B |
| Total Liabilities | 39.94B | 39.14B | 36.82B | 34.80B | 36.19B |
| Stockholders Equity | 39.11B | 36.66B | 35.65B | 34.53B | 33.68B |
Cash Flow | |||||
| Free Cash Flow | -5.43B | -2.96B | 1.28B | 2.01B | 2.02B |
| Operating Cash Flow | -3.31B | 627.00M | 2.85B | 3.50B | 3.23B |
| Investing Cash Flow | -3.17B | -3.54B | -1.37B | -1.55B | -978.00M |
| Financing Cash Flow | 7.62B | 14.00M | -813.00M | -1.67B | -2.45B |
Fuso Pharmaceutical Industries,Ltd. Technical Analysis
Fuso Pharmaceutical Industries,Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥8.85B | 16.22 | 2.53% | 2.90% | -21.60% | ||
70 Outperform | ¥5.40B | 18.41 | 3.34% | 5.93% | ― | ||
68 Neutral | ¥34.61B | 18.34 | 3.04% | 8.07% | -45.20% | ||
65 Neutral | ¥18.51B | 6.46 | 3.98% | 9.31% | -340.82% | ||
50 Neutral | ¥10.03B | 155.65 | 1.04% | 0.66% | -40.86% | ||
46 Neutral | C$197.02M | -3.33 | -23.14% | 2.65% | 20.75% | -0.36% |
Fuso Pharmaceutical Industries,Ltd. Corporate Events
Fuso Pharmaceutical Industries, Ltd. announced personnel changes in its executive officer team following a Board of Directors meeting on June 25, 2025. The changes include the appointment of new executive officers and the reappointment of six current members, indicating a strategic move to strengthen its leadership structure.
Fuso Pharmaceutical Industries, Ltd. has filed an appeal with the Supreme Court following a judgment in a patent infringement lawsuit involving their oral antipruritus agent, Nalfurafine Hydrochloride OD Tablets. The Intellectual Property High Court had previously ruled in favor of Toray Industries, Inc., ordering Fuso to pay over 7 billion yen in damages. The company maintains that their product does not infringe on Toray’s patent rights and is seeking a reversal of the decision.
Fuso Pharmaceutical Industries, Ltd. announced that there will be no revisions to its financial results forecast for the fiscal year ending March 31, 2026, despite a recent patent infringement lawsuit. The company also confirmed that there will be no changes to its dividend forecast, signaling stability in its financial outlook and commitment to shareholder returns.
Fuso Pharmaceutical Industries, Ltd. has entered into a special overdraft agreement with Sumitomo Mitsui Banking Corporation to secure mid- to long-term liquidity following a court ruling against them in a patent infringement lawsuit. This agreement, which is unsecured and has a contract limit of 8 billion yen, is intended to address financial obligations resulting from the judgment, although it will not affect the company’s financial forecast for the fiscal year ending March 31, 2026.
Fuso Pharmaceutical Industries, Ltd. announced corrections to its financial results for the fiscal year ended March 31, 2025, due to a provision for litigation losses related to a patent infringement lawsuit. This adjustment significantly impacts the company’s financial statements, resulting in an extraordinary loss for fiscal year 2024 and necessitating revisions to key financial documents.
Fuso Pharmaceutical Industries, Ltd. announced that the Intellectual Property High Court partially upheld a patent infringement claim by Toray Industries, Inc. regarding their product, Nalfurafine Hydrochloride OD Tablets. The court ordered Fuso to pay damages, impacting their financial results for the fiscal year ending March 2025. Fuso plans to appeal the decision to the Supreme Court, although their financial forecast for the fiscal year ending March 2026 remains unchanged.
Fuso Pharmaceutical Industries, Ltd. reported a significant improvement in its financial performance for the fiscal year ended March 31, 2025, with a notable increase in net sales and profits compared to the previous year. The company achieved a 9.3% increase in net sales and over 100% growth in operating and ordinary profits, indicating strong operational efficiency and market demand. The company also announced an increase in annual dividends per share, reflecting its robust financial health and commitment to shareholder returns.
Fuso Pharmaceutical Industries, Ltd. announced a change in its leadership structure, appointing Mikihiro Toda as a new Representative Director to enhance management efficiency and support its long-term growth strategy. Additionally, Yukari Ikeno has been nominated as a candidate for Outside Director, while Minoru Sudo will retire from his position as Outside Director.
Fuso Pharmaceutical Industries reported a significant improvement in its financial performance for the fiscal year ending March 31, 2025, with a notable increase in net sales and profits compared to the previous year. The company achieved a 9.3% rise in net sales and over 100% growth in operating and ordinary profits, reflecting strong operational efficiency and market demand. Despite these gains, the forecast for the next fiscal year anticipates a slowdown in profit growth, indicating potential challenges ahead.